Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients
Authors' conclusion
No difference in PFS between FNMTC and sDTC patients suggests comparable responsiveness to standard therapy.
Study context
- Population
- Patients with familial non-medullary thyroid carcinoma (FNMTC) and matched sporadic differentiated thyroid cancer (DTC) treated with standard therapymatched cohort
- Participants
- 65 vs 170
- Exposure
- FNMTC vs sporadic DTC
- FNMTCn = 65
- Sporadic DTC (sDTC)n = 170reference
- Outcome
- Progression-free survival (PFS)
Methodological detailslongitudinal, matched 1:3 on age, sex, ATA recurrence risk, extent of initial surgery and diagnosis date, 30 of 95 FNMTC patients excluded for lack of follow-up data
- Longitudinal
- Matched 1:3 on age, sex, ATA recurrence risk, extent of initial surgery and diagnosis date
- 30 of 95 FNMTC patients excluded for lack of follow-up data
Main finding
As reported in the abstract
Disease progression / PFS · median follow-up 4.73 (2.87-10.27) years FNMTC; 5.83 (2.33-10.79) years sDTC
FNMTC vs sDTC: P = 0.61 · FNMTC vs sDTC: P = 0.56
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Factors associated with PFSATA-R highvs ATA-R low | 9.2 (2.67–31.85) | P < 0.001 | |
| Factors associated with PFSMalevs Female | 2.5 (1.11–5.6) | P = 0.026 | |
| 0.050.21520Hazard ratio (log scale) |
Tumor size at presentation · smaller with FNMTC
P < 0.01
Repeated neck surgery for persistent/recurrent disease
P = 0.48
RAI therapy dosage · no difference
P = 0.82
- Positive lymph nodes at presentation · fewer with FNMTC
- P = 0.009
Original publication
Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients. Thyroid. Published 20 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →